Nichols & Pratt Advisers LLP Alnylam Pharmaceuticals, Inc. Transaction History
Nichols & Pratt Advisers LLP
- $1.5 Billion
- Q3 2024
A detailed history of Nichols & Pratt Advisers LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Nichols & Pratt Advisers LLP holds 1,375 shares of ALNY stock, worth $333,437. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,375Holding current value
$333,437% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
643Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.06 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.32 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.27 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.2 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...